Trial of Iloprost in Pulmonary Hypertension Secondary to Pulmonary Fibrosis

Interstitial Lung Disease Study Group, Korea

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Pulmonary Fibrosis; Pulmonary Hypertension

Treatments: Drug: Iloprost inhalation

Study type: Interventional

Funder types: NETWORK

Identifiers

NCT00439543

TILOPF

Details and patient eligibility

About

Idiopathic pulmonary fibrosis(IPF) is chronic progressive fibrosing lung disease of unknown cause. There is no effective therapy yet for this disease and the mean survival in most reports is about 3 years after the diagnosis. Because of the stiff fibrosis of the lung, pulmonary hypertension is the late complication of IPF and its development heralds a very poor outcome of the patients. For the primary pulmonary hypertension, recently the effective drugs have been available. However, there is no study about the efficacy of these drugs in the patients with pulmonary hypertension secondary to pulmnary fibrosis, and the aim of this trial is to study the safty and efficacy of "Iloprost," one of the safe and effective drugs in primary pulmonary hypertension.

Full description

• Prospective open labeled observational study
• Subjects: About 15 patients with secondary pulmonary hypertension due to IPF or pulmonary fibrosis associated with collagen vascular diseases.
• Method: 3 month trial of inhaled iloprost. Check the safty and measure the pulmonary arterial pressure by right heart catheterization, exercise capacity by 6 minute walking test, echocardiography, and quality of life questionnaires before and after the trial.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of idiopathic pulmonary fibrosis or fibrotic NSIP according to American Thoracic Society and European Respiratory Society guidelines by biopsy and diagnosis of pulmonary fibrosis associated with connective tissue disease.
• Mean pulmonary artery pressure over 30mmHg.
• NYHA functional class II to IV

Exclusion criteria

• Suffering lung diseases other than pulmonary fibrosis (COPD, Pulmonary Thromboendarterectomy ).
• Administration of prostanoids, bosentan, beta- blocker or phosphodiesterase5 inhibitor.
• Dosage adjustment of calcium channel blockers within 6 weeks.
• Resting pulmonary capillary wedge pressure over 15mmHg.
• Bleeding tendency.
• Bilirubin level above 3mg/dl or creatinine clearance level below 30ml/min.
• Unstable angina pectoris, myocardial infarction or severe arrhythmia within 6 months.
• Cerebrovascular accident within 6 months.
• Present lung infection.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)